OTTAWA, ONTARIO -- (Marketwired) -- 10/04/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug discovery, today announced that it has been selected, among a large group of candidates, to present at the prestigious BIO Investor Forum to be held in San Francisco October 17-18th at the Westin St. Francis Hotel. Robert (Bob) Bechard, Vice-President, Finance and Business Development of Tetra will present on Tuesday the 17th at 4:00pm Pacific Time (7:00pm Eastern Time). The presentation will be available live via webcast.
BIO Investor Forum is one of the premiere Investor/Bio-Partnering events providing access to more than 125 investment funds, 175 BioPharmaceutical companies and 800 delegates from all over the world, giving Tetra an excellent opportunity to present its robust product pipeline that is chasing multi-billion dollar markets including cancer pain, neuropathic pain, chemo induced vomiting and nausea, as well as dry eye, eye pain, and chronic pain. Tetra is the only company that has successfully run clinical trials using a smokable cannabis product recognized by Health Canada and the Food and Drug Administration (USA) and has generated Phase I results that demonstrated excellent bioavailability and safety data which has created great interest from pharmaceutical companies and Bio-Pharma investors. In addition to presenting Tetra will be holding one-on-one Investor and Partnering meetings to carefully identify future Investors and Partners and will also be advancing its discussions with partners met at previous conferences.
"It is indeed an honor to have been selected by BIO Investor Forum to present at this most prestigious conference. Our selection was based on the strength and innovation of our pipeline, with a potential of bringing novel therapies to huge number of patients and pursuing billion dollar markets. Events like BIO Investor enable us to get in contact with 100s of investors, companies, and delegates in a very short period of time, allowing us to cost-effectively spread the word on the enormous potential of our business model," said Bernard Fortier, CEO of Tetra Bio-Pharma. "We strongly believe in the future potential of our business strategy as we build Tetra into a global leader in cannabinoid-based drug discovery and development."
A link to the live audio webcast will be available on Tetra's website at http://tetrabiopharma.com/investors/presentations/default.aspx. The webcast will be archived for three months.
Furthermore, Tetra announces that on October 3rd, 2017, in accordance with the Company's stock option plan and subject to the approval of the Toronto Stock Exchange, the Board of Directors granted an aggregate of 1,400,000 incentive stock options ("options") to its officers and directors of the Company. Each option, vesting immediately upon grant, entitles the holder thereof to purchase one common share in the capital of the Company at a price of $0.69 per share until October 3, 2018 and October 3, 2021. The options and any common shares issued upon exercise thereof will be subject to a four-month resale restriction from the date of grant.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE: TBP)(OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Contacts:
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com
www.tetrabiopharma.com
